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The primary goal in the treatment of malignant obstruction is the relief of jaundice. Although operative
biliary bypass is a reliable method of palliation, nonoperative palliation may be desirable in selected
patients.
We report our experience with forty-eight self expandable metallic biliary endoprostheses (Wallstent)
percutaneously placed in 35 patients with irresectable malignant biliary obstruction. In twelve patients
more than one stent was necessary to bridge the entire length of the biliary stenosis. The obstruction was
due to primary tumors in 14 and to lymph node metastases in 12. In nine patients transanastomotic
stents were placed after previous bilioenteric anastomosis because of malignant obstruction.
Complications occurred in 11 patients (31.4%), and five patients died within 30 days of stent placement
(14.3%). The mean stent patency to date of patients discharged is 6.1 months, and the mean survival 7.2
months. Follow up data is available for 29 patients, and excellent palliation was achieved for more than
75% of the survival time in 22 (76%). Seven patients have had documented stent occlusion requiring
further intervention (24%).
In this selected group of patients, the results of percutaneous self-expandable stents are encouraging.
However, our data does not support the initial reports of self-expandable endoprostheses that suggest an
improved result compared to conventional plastic stents. A randomized study using either expandable
stents as compared to operative biliary enteric bypass is necessary.
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INTRODUCTION
Malignant biliary obstruction may be treated by operative or nonoperative meth-
ods. Operative resection should be performed when possible and provides relief of
biliary obstruction, with a chance of cure. However the majority of patients with
either primary or metastatic tumors are not amenable to curative resection 1’2.
Palliative relief of jaundice may be achieved by operative biliary bypass, or
transtumoral stenting3’4’5’6. Although operative bypass provides a reliable method
of palliation4’5, it is not always possible, and the relatively short life expectancy of
these patients suggests a less invasive alternative may be preferable if the method is
safe, effective, and does not require further intervention.
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Permanent stainless steel biliary endoprostheses have been developed, and
preliminary reports suggest improved results compared to conventional plastic
stents7-13. The reported advantages include safety of insertion, and a lower
incidence of stent occlusion and subsequent cholangitis1’12. This study describes
our initial experience with percutaneous placement of self-expandable biliary
endoprostheses (Wallstent) for irresectable malignant biliary obstruction.
MATERIALS AND METHODS
Between December 1988 and June 1991, 48 expandable biliary endoprostheses
were placed in 35 patients with malignant biliary obstruction. There were 16 males
and 19 females, with a mean age of 61.7 years (range 34-84). A single stent was
used in 23 patients. Eleven patients required two stents each, and one patient had
three stents placed. More than one stent was required in these patients to bridge
the entire length of the biliary stenosis. Twenty six of the 35 patients (74%) had
histologic proof of malignancy prior to stent placement, and malignancy was
evident by the clinical course of the remaining nine. The obstruction was due to a
primary tumor in 14 patients, and lymph node metastases in 12 (Table 1). In nine
patients the stents were placed for biliary obstruction after previous bilioenteric
anastomosis. Four of these patients had a history of resection and bypass of a tumor
originating from the gallbladder, pancreas or bile duct. Five patients had previously
been treated by a palliative bypass for irresectable cholangiocarcinoma. The
locations of the biliary obstruction were defined as: high (confluence, main hepatic
duct 11), middle (common hepatic duct, supraduodenal common bile duct-
10), distal (intrapancreatic- 5), and transanastomotic (after previous bilioenteric
anastomosis- 9).
In our institution we have pursued an aggressive policy of exploration for
possible resection of all patients with biliary and pancreatic tumors without
radiologically demonstrable contraindication to resection. Operative bypass is
selected in fit patients who are believed to be irresectable, if a suitable hepatic duct
Table 1
Etiology of Obstruction (N)
Primary tumor
cholangiocarcinoma 6
gallbladder 5
pancreas 3
Lymph node metastases
stomach 5
colon 4
breast 2
leiomyosarcoma
Previous bilioenteric anastomosis
cholangiocarcinoma 7
pancreas
gallbladder
14
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is available and when lobar liver atrophy is not present. Most patients reported in
this series were considered inoperable because of poor medical condition, or when
bile duct anatomy was not favorable for operation.
The decision to perform palliative drainage by the percutaneous route was made
at a multidisciplinary meeting involving surgeons, interventional radiologists and
gastroenterologists. The length of hospitalization included time for diagnostic
studies to determine resectability. All patients were managed on the surgical ward,
and routine follow up visits were done in the surgical outpatient clinic. Repeat
radiologic investigations were performed only if clinical symptoms suggested stent
occlusion. Early and late complications were documented, as well as the necessity
of repeat admissions or interventions. The serum bilirubin and alkaline phospha-
tase levels were measured at admission and compared to the level at discharge and
three months after stent placement.
TECHNIQUE OF INSERTION
All biliary interventions were performed after administration of prophylactic
antibiotics (Piperacillin). The endoprostheses were placed in two stages. A percuta-
neous transhepatic biliary drainage was first performed under local anesthesia. The
stent insertion was performed at a second session with local anesthesia, intravenous
sedation and cardiovascular monitoring. Infrequently, general anesthesia was
required.
An ultra thin guide wire (.018") was passed through a Chiba needle and advanced
into thecommon bile duct. The introducer set (Accustic-set, Boston Scientific) was
passed over a guide wire beyond the point of obstruction. The introducer was
exchanged for an 8.3 F Ring drainage catheter and maintained as an internal
external biliary drain for two to four days. After the temporary biliary drainage, the
stent insertion was performed by first introducing a 7 F sheath. A 7 F balloon
catheter (length 6 cm, diameter 10 mm) was used to dilate the stenosed bile duct.
The endoprosthesis (Wallstent, Schneider, Z/irich, Switzerland) mounted on the
tip of a 7 F introducer catheter, was passed over a guide wire distal to the stenosis.
After proper positioning of the endoprosthesis, additional balloon dilatation of the
stenosis and stent was performed. A drainage catheter was then left in the proximal
portion of the implanted endoprosthesis. At 24 to 48 hours post stent placement, a
repeat cholangiogram was performed to document the stent position and patency
(Figures 1 and 2). As the external catheter was removed, the hepatic puncture was
embolized with gelfoam strips. Antibiotic prophylaxis was continued until removal
of the external drainage catheter.
The transhepatic approach was used in 30 patients. Five patients had the limb of
a Roux-en-Y loop subcutaneously placed at the time of a previous operative biliary
enteric bypass. The stent was placed transjejunally in four of these patients, and
one required a combined endoscopic-transhepatic approach. Figure 3 shows the
metal stent in the expanded state.
RESULTS
Placement of the biliary endoprosthesis was possible in 35 of the 36 patients in178 A. GLTTLI ET AL.
Figure la Percutaneous transhepatic cholangiogram of a hilar cholangiocarcinoma (arrows) with
stenosis of right and left hepatic duct.
Figure lb Same patient with expandable stent (arrows) placed across the stenosis into the right hepatic
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Figure 2a Cholangiogram shows malignant recurrence at biliary enteric anastomosis (arrows).
Figure 2b Same patient with transanastomotic stent (arrows) placed across stenosis into the jejunal
loop.180 A. GLTTLI ET AL.
Figure 3 Wallstent in expanded state.
whom it was attempted. One patient died after failed stent placement and is
excluded from further analysis. The length of the hospitalization for stent place-
ment was a mean of 15 days (range 2-35 days). Eleven patients (31%) developed
complications within 30 days of stent placement. Cholangitis was the most frequent
(four patients), followed by pancreatitis in two and pneumonia, renal insufficiency
and a bleeding ulcer in one patient respectively; two complications were directly
related to the stent placement (6%). A duodenal perforation due to a guide wire
was managed conservatively, and a hepatic artery pseudoaneurysm was embolized
one month after stent placement. Five patients died within 30 days of stent
placement (14%). The deaths were due to persistent biliary sepsis in four patients,
and necrotizing pancreatitis in one.
One patient has been lost to follow up. Data are available on 29 patients
discharged from the hospital, and all have survived at least three months. Ten
patients have died (34%) at a mean of 8.5 months after stent placement. Nineteen
patients are alive (66%) after a mean of 6.6 months. The mean survival and stent
patency according to etiology and level of obstruction are listed in Table 2.
Excluding the terminal admission before death, 15 of 30 patients (50%) have
required repeat hospitalizations for episodes of cholangitis or recurrent jaundice.
Twelve patients have been admitted once, one patient twice, one patient four
times, and one five times. Seven patients have had documented stent occlusion
which required further intervention (24%) (Table 3). In three patients transhepatic
insertion of an expandable stent through the previous one was successful. In two
cases a conventional stent was endoscopically placed through the occluded self-
expandable prosthesis. Simple recannulization of the stent was used as an alterna-
tive in two patients.
The quality of the palliation was estimated by the proportion of patients whoBILIARY OBSTRUCTION 181
Table 2
Mean survival
Etiology (N) (months)
Stent patency
(months)
Primary tumors (14) 5.9 (3-13)
Metastases (10) 8.0 (3-15)
Anastomotic (5) 8.8 (5-13)
Level of obstruction
High (10) 6.4 (3-13)
Middle (9) 6.8 (3-15)
Iow () 8.0 (3-5)
Anastomotic (5) 8.8 (5-13)
Total (29) 7.2 (3-15)
a Refers to 29 patients discharged from hospital and available for follow up.
5.4(3-11)
6.6(3-15)
6.6(4-13)
5.5 (3-a)
5.3 (3-15)
8.0 (3-5)
6.6(4-13)
6.1(3-15)
Table 3
Reinterventions
Cause interval Treatment
Jaundice 6 months
Stent occlusion 6 months
Stent occlusion 6 months
10 months
14 months
Stent occlusion 8 months
Stent occlusion 4 months
Stent occlusion 3 months
Stent occlusion 5 months
Segment III bypass (operative)
Conventional stent
(endoscopic due to ascites)
Transhepatic recannulization
Transhepatic 2nd stent
Transhepawtic 3rd stent
Conventional stent
(endoscopic-percutaneous)
Transhepatic 2nd stent
Transhepatic 2nd stent
Transjejunal recannulization
survived until they developed debilitating episodes of cholangitis or stent occlusion
requiring hospitalization or repeat interventions. Twenty-two of 29 patients (76%)
were generally well during greater than 75% of their survival after stent placement.
Five patients (17%) were well 50% to 75% of the time after stent placement, and
two patients (7%) had adequate palliation for less than 50% of survival time.
DISCUSSION
A variety of options are available to relieve irresectable malignant obstruction. The
selection of the specific treatment for an individual patient is multifactorial, but the
relatively short life expectancy is one of the most important considerations. Biliary
enteric bypass has been shown to be a reliable method of palliation. There are
however, subsets of patients in whom operative bypass may be inappropriate due to182 A. GLA,TTLI ET AL.
lobar atrophy or nonavailability of a suitable bile duct. Some patients are not
suitable for operation due to poor medical condition which also makes nonopera-
tive relief of biliary obstruction preferable. Conventional plastic biliary stents have
been associated with frequent episodes of cholangitis and stent occlusion. The
incidence of documented stent occlusion depends upon the thoroughness of follow
up, but in large series, has been reported at 6-23% 2"4"15. Metal self expandable
endoprostheses were adapted from their initial use as vascular stents in an effort to
provide lasting relief of jaundice. Several centers have now reported experience
with these stents for both benign and malignant biliary obstruction7-3.
The expandable stents may be placed by either the endoscopic or transhepatic
route. It has been shown for conventional stents that endoscopic insertion is
superior to percutaneous placement in terms of 30-day mortality and success rate
for relief of jaundice 16. Endoscopic placement of expandable metal endoprostheses
has not yet been done by our gastroenterologists. Percutaneously placed expand-
able stents have theoretical advantages compared to conventional stents. The
conventional stent requires a 12-14 F hepatic puncture and results in a stent lumen
of 4 mm. Despite the smaller hepatic puncture of the expandable stent (7 F), it
results in a larger diameter after deployment (10 mm). Experimental work in
animals has identified mucosal proliferation along the bile duct wall which grows
between the metal filaments to form a new mucosal lining17. The incorporation of
the stent into the bile duct wall has been suggested as allowing a more physiologic
flow of bile and a reduction in the incidence of encrustation and subsequent
cholangitis as happens with conventional plastic stents.
Three models of expandable endoprostheses are currently available. The self
expandable Gianturco stent (Cook, Bloomington, IN) is made of stainless steel
wire. The balloon expandable Palmaz stent (Johnson and Johnson, Warren, NJ) is
a lattice of stainless steel. The Wallstent (Schneider, Zfirich, Switzerland) used in
this series is self expandable, and is composed of braided stainless monofilaments
(Figure 3). The Gianturco stent made of wires is more porous than the other
models, and tumor may grow more easily between the wires. In malignant biliary
obstruction, the narrow spaced braided Wallstents have been reported to have a
lower rate of tumor growth between the filaments (7%) as compared to the
Gianturco stent (50%).
The initial reports of expandable biliary endoprostheses have been encouraging
(Table 4). Comparisons between the different centers are difficult, as the patient
selection, indications for placement, and the method and depth of follow up
evaluation vary. Some of the series have reported few or no complications related
to stent placement, and only rare episodes of subsequent stent occlusion. Although
the patients we selected for stent placement were chosen by different criteria, this
has not been our experience. During the same time period, our mortality for biliary
enteric bypass in patients considered fit for operation was 11% (Baer et al.,
submitted for publication), a result similar to the 14% in the current series. The
incidence of perioperative complications after stent placement (31%) is also
considerable. It is possible that some or all of the patients with pancreatitis or
cholangitis after stent placement were due to progression of the disease and not
directly from the stent placement. The mean hospital stay of 15 days included
preoperative investigations to exclude resectability. In our experience, this is not a
procedure for outpatient or minimal hospitalization as others have suggested’11.
Most importantly, by having all of the follow up care in the same clinic, seven of theBILIARY OBSTRUCTION 183
Table 4
Author (n) Type stent
Series of expandable stents
Complications Mortality Occlusion Survival
Irving (16) Gianturco not listed 0%
Yoshioka (21) Gianturco not listed 10%
Coons (16) Gianturco not listed 0%
Adam (41) Wallstent 12% 7%
Neuhaus (35) Wallstent 0% 0%
Lammer (31) Wallstent 8% 7%
Cwikiel (16) Wallstent 11% 19%
Glitrtli (35) Wallstent 31% 14%
n: includes only malignant stenoses
Mortality: within 30 days of stent placement
Occlusion: documented occlusion reported
Survival: mean survival calculated from data within article
50% not listed
24% 97 days
19% not listed
5% 105 days
17% 134 days
13% not listed
31% 189
24% 218 days
29 patients available for follow up have had documented stent occlusion requiring
reintervention (24%), which is not less than after conventional stenting. We did not
identify any difference in survival or stent patency based on etiology or level of
biliary obstruction. We have been especially encouraged by the added months of
palliation in patients with anastomotic recurrence months to years after a prior
resection of a malignant tumor.
Self expandable biliary endoprostheses have an important role in the treatment
of irresectable malignant biliary obstruction. A randomized study of these patients
comparing expandable stents with operative biliary enteric bypass is necessary to
define the role of each option. The evaluation of endoscopic insertion of self
expandable metal endoprostheses should be part of such a study. Selection of
patients for palliative stent placement should include consultation with members of
different specialities to prevent potentially resectable patients from being denied an
attempt at curative resection and to choose the optimal palliative procedure.
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